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Abstract
Background: Infections are a common complication of RA with associated morbidity and mortality. The aetiology
of increased risk is complex and multifactorial. Despite this, strategies to mitigate against risk of infection including
vaccination are not always addressed in primary or secondary care with wide variation in practice from multiple
small single centre audits. This study was a large two-centre survey of vaccine uptake in routine clinical practice
and evaluated the relationship between vaccination and the burden of infection in RA patients.
Methods: A patient questionnaire was devised and disseminated through postal, clinic and phone survey at 2 UK
rheumatology centres, detailing past vaccination history, reasons for non-vaccination, and history of recent
infection. In a subset of patients, primary care vaccination data were also obtained.
Results: In total 929 patients responded to the survey. Over 85 % of patients were vaccinated against influenza,
however only 44 % were vaccinated against pneumococcus. The vast majority of vaccination was undertaken in
primary care. In the 12 months prior to the survey, 7.7 % of subjects recalled at least one episode of severe
infection requiring admission, and nearly 40 % reported receiving at least one course of antibiotics.
Conclusions: Infections are common in RA and Rheumatologists need to be adept at recognising at risk patients
and managing them appropriately. Influenza vaccination uptake is good whilst pneumococcal vaccination rates are
comparatively poor. Collaborative approaches between primary and secondary care are required to maximise
vaccine uptake, which is safe and recommended in RA patients.
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Background
Rheumatoid Arthritis (RA) is a chronic autoimmune in-
flammatory disorder that if untreated results in damage
to joints with irreversible changes that confer increased
morbidity and functional loss [1]. Patients with RA have
an increased burden of infections [2]. A retrospective
longitudinal cohort study by Doran et al. reported on 609
RA subjects with over 7700 patient years of cumulative
follow up, during which the infection rate was 70–80 %
higher in RA subjects than controls [3]. Subsequent co-
hort studies have reported similar findings [4, 5]. The in-
creased infection risk in RA is due to an interaction
between immunological dysfunction, exposure to potent
immunosuppressive agents and inherent disease activity
[6–9]. Approximately half of all serious infections in RA
patients are attributable to a respiratory tract focus. Na-
tional death registry data have confirmed an increased
standardised mortality ratio (SMR) in this population
(SMR males 1.8 [95 % Confidence Interval [CI] I 1.6, 2.0];
SMR females 2.1 [95 % CI 1.9, 2.3]) [10, 11]. Pneumococ-
cus is the most frequently causative microbe in patients
with pneumonia, responsible for approximately 50 % of
cases [12, 13].
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Rheumatologists need to be adept at managing infec-
tions as a consequence of therapies and taking oppor-
tunities to mitigate infection risk is a logical step.
Vaccination is a key example. Guidance from the British
Society of Rheumatology (BSR) and the Joint Committee
on Vaccination and Immunisation (JCVI) recommend
that patients with autoimmune rheumatic diseases
should be offered a single pneumococcal vaccination
(with a second ‘booster’ vaccination after 5 years in se-
verely immunocompromised individuals) and receive
seasonal influenza vaccination annually in accordance
with national guidelines. Vaccination in RA patients is
safe with no evidence to suggest worsening of disease
post-administration, however vaccination uptake re-
mains poor with published single-centre audits showing
wide variation in practice (vaccination uptake between
22 and 100 %) [14–16].
Methods
We undertook a clinical audit of vaccine uptake to de-
termine the proportion of RA patients receiving seasonal
influenza and pneumococcal vaccination, identify factors
associated with vaccination uptake and explore the rea-
sons for non-vaccination.
A cross sectional survey of vaccine uptake in RA pa-
tients was undertaken at 2 U.K. sites (King’s College
Hospital, London (KCH) and Fife Rheumatic Diseases
Unit, Scotland) between January and March 2014. A
patient questionnaire was developed in collaboration
with local and national rheumatologists (see Additional
file 1). The questionnaire was reviewed by a patient
focus group prior to dissemination via postal survey with
additional data capture through clinic attendance and
telephone survey. By completing the questionnaire, sub-
jects were giving their consent to participate. Data col-
lected included prior vaccination history measuring
uptake against national standards. The vaccination his-
tory time interval covered by the survey was not speci-
fied and any history of vaccination was captured. In a
subset of patients, vaccination history was confirmed by
primary care providers. At KCH, hospital episode statis-
tics (HES) submission data review alongside analysis of
the electronic record with discharge summaries pertaining
to admission was undertaken to validate patient reported
data regarding hospitalised infection (as confirmed by
ICD-10 coding).
Summary statistics were analysed using parametric
and non-parametric tests as appropriate, logistic regres-
sion was used to explore the relationship between vac-
cination and infection as provided in the survey data.
Subsequent analyses using data available from HES uti-
lised survival modelling, using Cox proportional hazards.
Adjustment for confounding variables was performed
using an inverse probability of treatment weighting
(IPTW) model. A logistic regression analysis was per-
formed to calculate the probability of each patient being
in the exposed or unexposed group based upon their
clinical characteristics chosen based upon univariate
analyses selecting variables with a p value < 0.1. The re-
ciprocal of this probability was then used as a weight in
the Cox regression model. Model diagnostics were per-
formed to ensure that the assumptions of proportional
hazards were not violated and to confirm that the
weights were appropriately balanced without extreme
weights or perfect prediction. No weights were greater
than 16. Multivariable adjustments were made for age,
gender, drug exposure and comorbidity. Analyses were
undertaken using STATA version 13.1.
The vaccination survey was approved by both hospital
clinical audit departments ements. Using the HRA deci-
sion tool and after seeking formal advice through the
hospital Research and Development department, formal
ethical approval was not required. All data collected was
anonymised and retrospective and met local data protec-
tion requirements.
Results
Baseline demographics of 929 patients included in ana-
lysis are presented in Table 1. Vaccination was primarily
undertaken in the community setting (96 % of all vaccin-
ation) with pneumococcal and influenza vaccination
rates similar across both sites. Influenza vaccination was
offered to over 90% of patients(841/929)and was admin-
istered in 85.9% of patients (798/929) (Table 2).
Pneumococcal vaccination rates were poor with 44 % of
patients immunised.
In patients not offered either vaccination, the main rea-
son cited was that vaccination wasn’t recommended; 22
patients actively declined vaccination due to fear of wors-
ening disease control. In a multivariable logistic regression
model containing age, gender, smoking status, comorbid-
ity and anti-rheumatic therapy, the only statistically sig-
nificant variables to predict vaccination were comorbid
illnesses (Odds Ratio [OR] 1.79 (95%CI 1.34 to 2.39)) and
biologic therapy (OR 1.69 (95%CI 1.23 to 2.32)).
Table 1 Baseline demographics population
All n = 929 HES linked site only n = 387
Age (yrs.) 63.1 64.1
Gender Female n (%) 686 (74.9) 302 (78.1)
DMARDs n (%) 731 (78.7) 305 (78.8)
MTX n (%) 490 (52.7) 223 (57.6)
Biologics n (%) 240 (25.8) 109 (28.2)
Current smoker n (%) 191 (20.6) 54 (14.0)
Comorbidity n (%) 306 (32.9) 127 (32.8)
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Overall 72/929 (7.8 %) patients reported at least 1 ad-
mission to secondary care with an infection in the pre-
ceding year. Limiting just to the hospital site with
linkage to HES to validate reported infections, 35/327
(10.7 %) patients experienced at least 1 hospitalised in-
fection. Three hundred and sixty-nine patients (40 %) re-
ported being prescribed at least 1 antibiotic course by
their primary care physician within the preceding year.
As the majority of patients were vaccinated against in-
fluenza, analysis of the effect of this vaccination on in-
fection rate wasn’t possible. The rate of admission
amongst patients who received pneumococcal vaccin-
ation was lower than those who reported not having re-
ceived pneumococcal vaccination, although the odds of
recalling an admission were not significantly different:
OR 0.75 (95 % CI 0.46 to 1.24; p = 0.266). After adjusting
for age, gender, comorbidity, and smoking status the OR
was 0.61 (95 % CI 0.37 to 1.03).
Discussion
This study is the largest UK survey of vaccination uptake
in RA patients. The high uptake of influenza vaccination
represents a positive and proactive attitude towards vac-
cination from both rheumatologists and primary care
physicians. The findings of influenza vaccine uptake are
very favourable with previously published audits and
show successful uptake of vaccination in the community.
There was a striking disparity between influenza and
pneumococcal vaccine uptake. The reasons for this are
likely to be multifactorial, including lack of awareness,
organisation barriers to administration and possibly
negative perception of the safety of vaccines [17].
Increasing public perception of both influenza and
pneumococcal infection as significant threats to health
and encouraging vaccination as an effective preventive
strategy may correlate with a higher uptake of vaccin-
ation. Housden et al. reported a four-fold reduction in
both admissions and case fatality rates due to respiratory
tract infection in RA patients following the implementa-
tion of a successful ‘rheumatologist led’ vaccination
programme [18]. Together with rationalising immuno-
suppressive agents and minimising steroid exposure,
vaccination is a modifiable risk factor that can mitigate
against infection. Although rheumatologists are respon-
sible for the initiation of immunosuppressive agents, at
present it remains in the domain of the GP to ensure
vaccination administration. Primary care practices are
commissioned to vaccinate people over 65 and those
under 65 at risk (i.e. immunosuppressed patients)
against influenza and pneumococcus and are remuner-
ated accordingly through the NHS ‘Enhanced Services
Payment’ scheme.
Fear of side effects of vaccination has previously been
reported as a strong negative influence, while lack of
general motivation and ignorance about the recommen-
dations are other commonly reported barriers to both
seasonal and pandemic vaccination [19]. Information
pertaining to vaccination in RA is freely available to fur-
ther educate patients on the risks of infection and bene-
fits of vaccination; such resources should be utilised in
routine clinical care (http://goo.gl/y1zvyp).
Biologic prescription was significantly associated with
increased uptake of pneumococcal vaccination. This is
likely to be a reflection of departmental protocols advis-
ing pre-screening of patients and written correspond-
ence to GPs encouraging vaccine administration prior to
the commencement of biologic therapy. Age was not a
predictor of influenza or pneumococcal vaccination, a
surprising observation considering the national schedule
for vaccination advocating vaccination in people over 65.
It was not possible to assess the impact of individual
biologic agents on infection due to the relatively small
sample size, however a recent review article has
reviewed the current literature pertaining to individual
DMARD and biologic agents and infection risk in RA
[20].
Fewer infections were reported in patients who re-
ceived pneumococcal vaccination. Although not a statis-
tically significant finding, it is an intriguing observation
as reported infections were not exclusively limited to
pneumococcus. This may reflect bias within the study,
or an alternative explanation is that the proportions of
respiratory infections attributable to pneumococcus are
underestimated.
Hospitalised infective episodes represent the tip of the
iceberg when considering infections in RA. The infection
rate in the study cohort was is in keeping with published
rates and suggests that the study sample was representa-
tive of a standard RA population. It is advised that all
patients should have a formal risk assessment of
Table 2 Vaccination status of the study population













n < 65 years = 467
n > 65 years = 462
Total n (%) 841 (90.5) 410 (44.1) 798 (85.9) 412 (44.3)
Age <65 years n (%) 421 (90.1) 203 (43.5) 400 (85.7) 207 (44.3)
Age >65 years n (%) 420 (90.9) 207 (44.8) 398 (86.1) 205 (44.4)
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infection risk prior to commencing immunosuppressive
agents. The ‘RABBIT’ tool (http://www.biologika-regis-
ter.de/en/home/) helps to estimate the probability of ser-
ious infection within 12 months of commencing
treatment and was developed with data from over 5000
patients with RA who were recruited to the German bio-
logics registry with validation in a subsequent cohort of
nearly 3000 patients [21, 22]. Although it doesn’t replace
clinical judgement, the high agreement between ob-
served and predicted infections allows clinicians to make
informed decisions when balancing treatment versus in-
fection risk. A particular strength of the RABBIT score
is that it accommodates for time varying factors such as
infections within previous 12 months. It is known that
prior history of infection predicts future infection [21].
Caution must be exercised as the RABBIT score has not
been validated in the UK RA patients.
Vaccine efficacy may also be affected by choice of im-
munosuppressive therapy. Methotrexate, rituximab and
abatacept are associated with decreased immunogenicity
to both influenza and pneumococcal vaccination, how-
ever TNF inhibitors, tocilizumab and sulfasalazine do
not appear to have a negative effect on vaccine immuno-
genicity (albeit limited data for the latter two) [23]. Al-
though the humoral response to vaccination may be
muted with certain immunosuppressive agents, protect-
ive titres may still be achieved thus conferring the
intended protective effect of vaccination. Reporting on 152
patients with RA, Coulson and colleagues found no signifi-
cant correlation between pneumococcal antibody levels
and time since pneumococcal vaccination and suggested
that a single administration of pneumovax offered up to
10 years protection against the development of pneumo-
coccal pneumonia in RA patients on methotrexate [24].
The nature of the survey study design means that it
was prone to recall bias. Validation of vaccination status
from GP and HES data was congruent with patient re-
ported data. It is more likely that recall bias was associ-
ated with pneumococcal vaccination and the authors
concede the true number of vaccinated subjects may
have been underestimated. In future audits, correlation
with the primary care record would ensure the data
would be more robust with access to national HES data
improving data capture of hospital admissions due to in-
fection. Additionally, the number of antibiotic courses
prescribed in the community was a self-reported variable
and not confirmed with practice data and this is another
source of bias. Comorbidity data may have been subject
to misclassification bias, a perpetual risk of routinely
captured data. There was likely selection bias in who
was recruited to the audit as patients were not sent any
reminders to complete the postal survey. It is difficult to
predict the vaccination status of patients who chose not
to participate in the survey.
A challenge in the analysis was addressing steroid
exposure as it was not possible to account for inter-
mittent steroid therapy, variable oral dosing over time
or the administration of parenteral steroids. Thus no
adjustment was made for the dose of steroid and its
relationship to infection risk. The impact of steroid
(even at modest doses of <7.5 mg daily) on infection
risk is well established. Wolfe et al. demonstrated a
dose related association between prednisolone dosage
and pneumonia hospitalisation in patients with RA
[25]. Steroid and infection risk in RA has been the
subject of a meta-analysis of observational studies
which found corticosteroids were associated with an
increase in all-site serious infection (RR: 1.89;95 % CI:
1.60–2.24), lower respiratory tract infections (RR:
2.10; 95 % CI: 1.52–2.91), tuberculosis (RR: 1.74;
95 % CI: 1.09–2.76) and herpes zoster (RR: 1.74;
95 % CI: 1.28–2.36) with a dose-related increase in
risk of infection [26].
It was not possible to correct for unmeasured co-
founders such as severity of chronic lung disease
which would impact on susceptibility to infection and
choice of immunosuppressive agent. Prior hospitalisa-
tion is a predictor for future admissions with severe
infection and it wasn’t possible to correct for this in
the study but it is a factor that should be part of in-
fection assessment in RA patients. It was not possible
to demonstrate the relationship between pneumococ-
cal vaccination and infection over time due to the
size of the population, however this is an area of po-
tential interest for future studies.
Conclusions
This study highlights the need to raise the awareness of
vaccination amongst patients and primary care providers
in order to mitigate risk of infection. Pneumococcal vac-
cine uptake in particular consistently appears to be low.
Pneumococcal and influenza vaccinations are safe in
rheumatic disease and should be encouraged as part of
holistic management in RA. Vaccination takes place pri-
marily in the community setting, and pathways to im-
proving vaccination will require engagement between
primary and secondary care. The rheumatology commu-
nity need to recognise this crucial link, acknowledging
that our patients are at risk of falling between services if
the rheumatologist does not take responsibility for en-
suring vaccination uptake. In addition, rheumatologists
should address modifiable risk factors, select the safest
combinations of immunosuppression, and where pos-
sible minimise prescription of steroids. Regular assess-
ment of infection risk and consideration of infection
history are also key in ensuring holistic and personalized
management of patients with RA.
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